Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q3 2021 Earnings Presentation
18 slides from Indivior Pharmaceuticals's earnings presentation, Oct 28, 2021
Slide 1: Indivior PLC Q3 / YTD 2021 Results
Indivior PLC Q3 / YTD 2021 Results October 28, 2021
Slide 2: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 3: Forward-looking statements
Forward-looking statements This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from
Slide 4: Q3 2021 key messages
Q3 2021 key messages Continued good SUBLOCADE® growth – 5th consecutive quarter of double-digit growth in net revenue and patient dispenses Organized Health Systems (OHS) strategy driving SUBLOCADE® momentum Raising FY 2021 Total NR and SUBLOCADE® NR guidance 4
Slide 5: OHS strategy execution is driving SUBLOCADE growth
OHS strategy execution is driving SUBLOCADE® growth SUBLOCADE® NR Growth through the COVID Period OHS strategy is now fully embedded ($ in millions) OHS now accounts for ~55% of $70 $65 SUBLOCADE NR $60 $54* Activation in place with 300+ $50 $43 organizations (goal to activate 500+ $39 $40 $33 $29 $
Slide 6: Strategic Priorities report card: Q3 2021
Strategic Priorities report card: Q3 2021 1 2 3 4 Grow SUBLOCADE® >$1 bil. Diversify Revenue Build Our Pipeline Optimize Operating Model • Q3 21 NR: $65m • PERSERIS® Q3 21 NR: $5m • SUBLOCADE® label: updated to • Cash: $1.005 billion +7% vs. Q2 21 (+20% excl. $7m +25% vs. Q2 21; +67% vs. Q3 include
Slide 7: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 8: Q3/YTD 2021 financial highlights
Q3/ YTD 2021 financial highlights Strong top-line progression, FY 21 guidance raised* • Q3 YOY NR growth: +18% to $187m; YTD YOY NR growth: +23% to $568m • SUBLOCADE® Q3 YOY NR growth: +97% to $65m; SUBLOCADE® YTD YOY NR growth: +86% to $169m Investing to accelerate LAI growth • SUBLOCADE® – digital
Slide 9: Profit & Loss Account
Profit & Loss Account* Q3 YTD 2021 2020 % 2021 2020 % Adjusted Adjusted change Adjusted Adjusted change ($ in mil. at actual FX) Net Revenues 187 159 18% 568 462 23% Cost of Sales (26) (28) (88) (63) Gross Profit 161 131 23% 480 399 20% Gross Margin (%) 86% 82% +400bps 85% 86% -100bps Selling, Gener
Slide 10: Cash & borrowing position
Cash & borrowing position YTD FY • Net cash growth to $756m (vs. $623m at FY 2020): ($ in mil.) 2021 2020 Stronger YTD operating performance Cash & Cash Equivalents $1,005 $858 Stable government payables BUPREX® / BUPREXX / Temgesic® sale proceeds • Maintaining disciplined & balanced cash stan
Slide 11: Upgrading FY 2021 total net revenue and SUBLOCADE guidance
Upgrading FY 2021 total net revenue and SUBLOCADE® guidance Revised FY 2021 Guidance ($ in mil.) Additional top-line items: Total NR: $750m to $770m; +18% YOY at mid-point • Continued underlying BMAT market growth (previously $705m to $740m) • Relatively stable SUBOXONE® Film share levels in the US*
Slide 12: SUBOXONE Film indication and safety information
SUBOXONE® (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND USAGE SUBOXONE® Film is indicated for treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support HIGHLIGHTED SAFETY INFORMATION Prescr
Slide 13: SUBLOCADE indication and safety information
SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment f
Slide 14: About PERSERIS indication and safety information
ABOUT PERSERIS® (risperidone) for extended-release injectable suspension INDICATION PERSERIS® (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed w
Slide 15: Appendix
Appendix ocus on you.
Slide 16: Q3 Profit & Loss Account Reconciliation
Q3 Profit & Loss Account Reconciliation Q3 2021 Q3 2020 Q3 2021 Q3 2021 Q3 2020 Q3 2020 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 187 187 159 159 Cost of Sales (26) (26) (33) 51 (28) Gross Profit 161 161 126 131 Selling, General and Administration Expenses (112
Slide 17: YTD Profit & Loss Account Reconciliation
YTD Profit & Loss Account Reconciliation YTD 2021 YTD 2020 YTD 2021 YTD 2021 YTD 2020 YTD 2020 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 568 568 462 462 Cost of Sales (88) (88) (74) 11 1 (63) Gross Profit 480 480 388 399 Selling, General and Administration Expe
Slide 18: Upcoming events
Upcoming events • November 15th: Stifel Virtual Healthcare Conference Fireside chat and 1x1’s • November 16th: Jefferies London Healthcare Conference Presentation and 1x1’s 18